On April 18, 2026, ibogaine—a psychoactive compound derived from the root bark of the Tabernanthe iboga shrub—has surged into public discourse.
Recent discussions have featured prominent figures like Donald Trump and Joe Rogan. Trump remarked, “Can I have some, please?” highlighting the growing interest in this controversial substance.
As of midday, ibogaine’s effects on opioid receptors and dopamine pathways are under scrutiny. Patients often report significant reductions in withdrawal symptoms and cravings after treatment.
However, the experience can last from 12 to 36 hours and may involve vivid visions. This unpredictability raises concerns about safety—at least 27 deaths have been documented following ibogaine use.
The FDA has received an executive order to facilitate access to psychedelic drugs, including ibogaine. The Department of Health will allocate at least $50 million for developing programs targeting serious mental illnesses.
Texas previously approved $50 million for ibogaine research last year. This funding underscores a shift toward exploring psychedelics as viable treatment options.
Joe Rogan stated, “Ibogaine, in particular, has helped a lot of people. It gives you, like, a review of your life, apparently.” His comments reflect a growing belief in the therapeutic potential of psychedelics.
Details remain unconfirmed regarding the long-term implications of these developments. As research progresses, the impact on addiction treatment could be profound.